This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Infinity Reports Phase 1 Data For IPI-145 At ACR/ARHP Supporting Development In Inflammatory Conditions

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced new data from its completed Phase 1 study of IPI-145, the company’s potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data showed that IPI-145 was well tolerated and demonstrated favorable pharmacokinetics following administration of single and multiple doses in healthy adult subjects. Infinity also presented data demonstrating the activity of IPI-145 in preclinical models of rheumatoid arthritis (RA). These findings were presented at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting held in Washington, DC.

“These data show that IPI-145 is well tolerated in healthy subjects and inhibits immune cell activation even at low doses,” stated Vito J. Palombella, chief scientific officer at Infinity. “The profile of IPI-145 observed in this Phase 1 trial, combined with our preclinical studies in inflammation, support Phase 2 clinical development in patients with asthma and RA as well as other potential inflammatory indications.”

The PI3Ks are a family of enzymes involved in multiple cellular functions, such as cell proliferation and survival, metabolism, cell differentiation and cellular trafficking. 1 PI3K-delta and -gamma, two isoforms of PI3K, are necessary for adaptive and innate immunity, and the role of these enzymes in various immune cells supports the development of IPI-145 for the treatment of inflammatory disorders as well as hematologic malignancies. 2 Infinity believes that IPI-145 is the only PI3K-delta and -gamma inhibitor currently in clinical development.

Data Presented at ACR/ARHP

The Phase 1, double-blind, randomized, placebo-controlled trial of IPI-145 in healthy adult subjects evaluated single doses of IPI-145 ranging from 1 mg to 30 mg. Multiple doses of IPI-145 ranging from 1 mg twice daily (BID) to 5 mg BID for 14 days and 10 mg once daily (QD) for 14 days were also evaluated. In addition, the effect of food on the pharmacokinetics of IPI-145 was studied. One hundred six patients were enrolled in the Phase 1 trial.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs